Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, Sifakis F, Groothuis JR.

Pediatr Infect Dis J. 2014 Jun;33(6):576-82. doi: 10.1097/INF.0000000000000219.

2.

Definition and outpatient management of the very low-birth-weight infant with bronchopulmonary dysplasia.

Groothuis JR, Makari D.

Adv Ther. 2012 Apr;29(4):297-311. doi: 10.1007/s12325-012-0015-y. Epub 2012 Apr 16. Review.

PMID:
22529025
3.

Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008.

Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ.

Clin Epidemiol. 2011;3:245-50. doi: 10.2147/CLEP.S17189. Epub 2011 Sep 29.

4.

Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.

Fryzek JP, Martone WJ, Groothuis JR.

Adv Ther. 2011 Mar;28(3):195-201. doi: 10.1007/s12325-010-0106-6. Epub 2011 Feb 7. Erratum in: Adv Ther. 2011 Dec;28(12):1126.

PMID:
21327753
5.

Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.

Groothuis JR, Hoopes JM, Jessie VG.

Adv Ther. 2011 Feb;28(2):91-109. doi: 10.1007/s12325-010-0100-z. Epub 2011 Feb 4. Review.

PMID:
21318606
6.

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.

Groothuis JR, Hoopes JM, Hemming VG.

Adv Ther. 2011 Feb;28(2):110-25. doi: 10.1007/s12325-010-0101-y. Epub 2011 Feb 4. Review.

PMID:
21318605
7.

Preliminary clinical findings on NEUMUNE as a potential treatment for acute radiation syndrome.

Stickney DR, Groothuis JR, Ahlem C, Kennedy M, Miller BS, Onizuka-Handa N, Schlangen KM, Destiche D, Reading C, Garsd A, Frincke JM.

J Radiol Prot. 2010 Dec;30(4):687-98. doi: 10.1088/0952-4746/30/4/004. Epub 2010 Dec 8.

PMID:
21149931
8.

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.

Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR; Palivizumab Long-Term Respiratory Outcomes Study Group.

J Allergy Clin Immunol. 2010 Aug;126(2):256-62. doi: 10.1016/j.jaci.2010.05.026. Epub 2010 Jul 10.

PMID:
20624638
9.

A novel active respiratory syncytial virus surveillance system in the United States: variability in the local and regional incidence of infection.

Boron ML, Edelman L, Groothuis JR, Malinoski FJ.

Pediatr Infect Dis J. 2008 Dec;27(12):1095-8. doi: 10.1097/INF.0b013e3181812c8e.

PMID:
18989237
10.

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.

Speer ME, Fernandes CJ, Boron M, Groothuis JR.

Pediatr Infect Dis J. 2008 Jun;27(6):559-61. doi: 10.1097/INF.0b013e3181673c15.

PMID:
18434935
11.

Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database.

Simon A, Ammann RA, Wilkesmann A, Eis-Hübinger AM, Schildgen O, Weimann E, Peltner HU, Seiffert P, Süss-Grafeo A, Groothuis JR, Liese J, Pallacks R, Müller A; DSM RSV Paed Study Group.

Eur J Pediatr. 2007 Dec;166(12):1273-83. Epub 2007 Feb 16.

PMID:
17943313
12.

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL; Palivizumab Long-Term Respiratory Outcomes Study Group.

J Pediatr. 2007 Jul;151(1):34-42, 42.e1.

PMID:
17586188
13.

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course.

Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, Stephan V, Rieger C, Herting E, Wygold T, Hornschuh F, Groothuis JR, Simon A; DSM RSV Ped Study Group.

Pediatr Infect Dis J. 2007 Jun;26(6):485-91.

PMID:
17529864
14.

Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control.

Simon A, Khurana K, Wilkesmann A, Müller A, Engelhart S, Exner M, Schildgen O, Eis-Hübinger AM, Groothuis JR, Bode U.

Int J Hyg Environ Health. 2006 Jul;209(4):317-24. Epub 2006 May 11.

PMID:
16697255
15.
16.

Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003.

Schmidt AC, Johnson TR, Openshaw PJ, Braciale TJ, Falsey AR, Anderson LJ, Wertz GW, Groothuis JR, Prince GA, Melero JA, Graham BS.

Virus Res. 2004 Nov;106(1):1-13. Review.

PMID:
15522442
17.

Randomized, open-label preference study of two cyclosporine capsule formulations (usp modified) in stable solid-organ transplant recipients.

Steinberg SM, Venuto RC, Kuruvila CK, Taylor DO, Anil Kumar MS, Groothuis JR, Ryan J, Greco R, Yeldandi V, Ashraf T, Boodhoo T; Prefer Study Group.

Clin Ther. 2003 Jul;25(7):2037-52.

PMID:
12946549
18.
19.

Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.

Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, Baarsma R, Valido M, Pollack PF, Groothuis JR; Second Season Safety Study Group.

Drug Saf. 2003;26(4):283-91.

PMID:
12608889
20.

Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.

Pollack P, Groothuis JR.

J Infect Chemother. 2002 Sep;8(3):201-6. Review.

PMID:
12373481
21.

Respiratory syncytial virus prophylaxis--the story so far.

Simoes EA, Groothuis JR.

Respir Med. 2002 Apr;96 Suppl B:S15-24. Review.

22.
24.

The pitfalls of using managed care databases in cost-effectiveness research.

Groothuis JR.

Pediatrics. 1999 Nov;104(5 Pt 1):1124-5. No abstract available.

PMID:
10545557
25.

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.

Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA.

Antimicrob Agents Chemother. 1999 May;43(5):1183-8.

26.

Respiratory syncytial virus immune globulin and conflict of interest.

Groothuis JR.

N Engl J Med. 1998 Nov 26;339(22):1644. No abstract available.

PMID:
9867534
27.

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.

Simoes EA, Sondheimer HM, Top FH Jr, Meissner HC, Welliver RC, Kramer AA, Groothuis JR.

J Pediatr. 1998 Oct;133(4):492-9.

PMID:
9787686
28.
29.

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children.

Rodriguez WJ, Gruber WC, Groothuis JR, Simoes EA, Rosas AJ, Lepow M, Kramer A, Hemming V.

Pediatrics. 1997 Dec;100(6):937-42.

PMID:
9374560
30.

Immunoprophylaxis and the control of respiratory syncytial virus disease.

Meissner HC, Groothuis JR.

Pediatrics. 1997 Aug;100(2 Pt 1):260-3. No abstract available.

PMID:
9240809
31.

Room air challenge: prediction for successful weaning of oxygen-dependent infants.

Simoes EA, Rosenberg AA, King SJ, Groothuis JR.

J Perinatol. 1997 Mar-Apr;17(2):125-9.

PMID:
9134511
32.

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.

Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.

Pediatrics. 1997 Mar;99(3):454-61.

PMID:
9041304
33.

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin.

Meissner HC, Welliver RC, Chartrand SA, Fulton DR, Rodriguez WJ, Groothuis JR.

Pediatr Infect Dis J. 1996 Dec;15(12):1059-68. Review. No abstract available.

PMID:
8970212
34.

The potential role of gastroesophageal reflux in the pathogenesis of food-induced wheezing.

Meer S, Groothuis JR, Harbeck R, Liu S, Leung DY.

Pediatr Allergy Immunol. 1996 Nov;7(4):167-70.

PMID:
9151336
35.

Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children.

Simoes EA, Groothuis JR, Tristram DA, Allessi K, Lehr MV, Siber GR, Welliver RC.

J Pediatr. 1996 Aug;129(2):214-9.

PMID:
8765618
36.

Immunology of non-viral respiratory tract infections.

Rieger CH, Groothuis JR.

Pediatr Allergy Immunol. 1996;7(9 Suppl):91-4. Review. No abstract available.

PMID:
9156739
38.

Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.

Groothuis JR, Simoes EA, Lehr MV, Kramer AA, Hemming VG, Rodriguez WJ, Arrobio J, Welliver RC, Siber GR.

Antimicrob Agents Chemother. 1995 Mar;39(3):668-71.

39.

Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Hemming VG, Prince GA, Groothuis JR, Siber GR.

Clin Microbiol Rev. 1995 Jan;8(1):22-33. Review.

40.

Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial.

Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, Johnson G, Van Dyke R, Groothuis JR, Arrobio J, et al.

J Pediatr. 1994 Jul;125(1):129-35.

PMID:
8021762
43.

Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children.

Groothuis JR, Lehr MV, Levin MJ.

Vaccine. 1994 Feb;12(2):139-41.

PMID:
8147095
45.

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, et al.

N Engl J Med. 1993 Nov 18;329(21):1524-30.

46.

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Meissner HC, Fulton DR, Groothuis JR, Geggel RL, Marx GR, Hemming VG, Hougen T, Snydman DR.

Antimicrob Agents Chemother. 1993 Aug;37(8):1655-8.

47.

Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection.

Simoes EA, King SJ, Lehr MV, Groothuis JR.

Am J Dis Child. 1993 Mar;147(3):303-6.

PMID:
8438813
48.

Immunoprophylaxis and immunotherapy: role in the prevention and treatment of repiratory syncytial virus.

Groothuis JR, Simoes EA.

Int J Antimicrob Agents. 1993 Feb;2(2):97-103.

PMID:
18611528
49.

Immune response to split-product influenza vaccine in preterm and full-term young children.

Groothuis JR, Levin MJ, Lehr MV, Weston JA, Hayward AR.

Vaccine. 1992;10(4):221-5.

PMID:
1561829
50.

Antibody responses to influenza B viruses in immunologically unprimed children.

Levandowski RA, Regnery HL, Staton E, Burgess BG, Williams MS, Groothuis JR.

Pediatrics. 1991 Nov;88(5):1031-6.

PMID:
1945607

Supplemental Content

Loading ...
Support Center